These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32158975)

  • 21. Improving clinical outcomes for women with overactive bladder or urinary retention symptoms: a comparison of motor response voltages (1-9 V) during Stage 1 sacral neuromodulation.
    Marinkovic SP; Ford JC
    BJU Int; 2018 Sep; 122(3):472-479. PubMed ID: 29637712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors for explantation due to infection after sacral neuromodulation: a multicenter retrospective case-control study.
    Myer ENB; Petrikovets A; Slocum PD; Lee TG; Carter-Brooks CM; Noor N; Carlos DM; Wu E; Van Eck K; Fashokun TB; Yurteri-Kaplan L; Chen CCG
    Am J Obstet Gynecol; 2018 Jul; 219(1):78.e1-78.e9. PubMed ID: 29630890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
    Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real World Performance of Sacral Neuromodulation and OnabotulinumtoxinA for Overactive Bladder: Focus on Safety and Cost.
    Chughtai B; Clemens JQ; Thomas D; Sun T; Ghomrawi H; Sedrakyan A
    J Urol; 2020 Jan; 203(1):179-184. PubMed ID: 31347949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of prior back surgery on neuromodulation outcomes: A review of over 500 patients.
    Bartley JM; Killinger KA; Boura JA; Gupta P; Gaines N; Gilleran JP; Peters KM
    Neurourol Urodyn; 2017 Aug; 36(6):1535-1542. PubMed ID: 27676460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
    Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
    Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sleep Disturbance and Fatigue Are Associated With More Severe Urinary Incontinence and Overactive Bladder Symptoms.
    Ge TJ; Vetter J; Lai HH
    Urology; 2017 Nov; 109():67-73. PubMed ID: 28826875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-in-human implantation of a mid-field powered neurostimulator at the sacral nerve: Results from an acute study.
    van Kerrebroeck PEVA; Reekmans M; van Koeveringe GA; Yeh AJ; Fayram TA; Sharan AD; Comiter CV
    Neurourol Urodyn; 2019 Aug; 38(6):1669-1675. PubMed ID: 31107559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of the rechargeable sacral neuromodulation system to treat refractory overactive bladder.
    Albabtain M; Chughtai B; Cho A; Elterman D
    Ther Deliv; 2021 May; 12(5):353-362. PubMed ID: 33821666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variation in bony landmarks and predictors of success with sacral neuromodulation.
    Husk KE; Norris LD; Willis-Gray MG; Borawski KM; Geller EJ
    Int Urogynecol J; 2019 Nov; 30(11):1973-1979. PubMed ID: 30729252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes in a contemporary cohort undergoing sacral neuromodulation using optimized lead placement technique.
    Adelstein SA; Lee W; Gioia K; Moskowitz D; Stamnes K; Lucioni A; Kobashi KC; Lee UJ
    Neurourol Urodyn; 2019 Aug; 38(6):1595-1601. PubMed ID: 31044466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Refractory overactive bladder after urethrolysis for bladder outlet obstruction: management with sacral neuromodulation.
    Starkman JS; Duffy JW; Wolter CE; Kaufman MR; Scarpero HM; Dmochowski RR
    Int Urogynecol J Pelvic Floor Dysfunct; 2008 Feb; 19(2):277-82. PubMed ID: 17671752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What Is New in Neuromodulation?
    Moore CK; Rueb JJ; Derisavifard S
    Curr Urol Rep; 2019 Aug; 20(9):55. PubMed ID: 31388779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sacral nerve stimulation for refractory overactive bladder in the elderly population.
    White WM; Mobley JD; Doggweiler R; Dobmeyer-Dittrich C; Klein FA
    J Urol; 2009 Oct; 182(4):1449-52. PubMed ID: 19683295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single Institutional Experience with Single Stage Sacral Neuromodulation: Cost Savings and Outcomes in a Contemporary Case Series.
    Lee W; Artenstein D; Tenggardjaja CF; Lee UJ; Lucioni A; Reyblat P; Kobashi KC
    J Urol; 2020 Mar; 203(3):604-610. PubMed ID: 31584846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuromodulation in urology, state of the art.
    Ammirati E; Giammò A; Manassero A; Carone R
    Urologia; 2019 Nov; 86(4):177-182. PubMed ID: 31368415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sacral neuromodulation for overactive bladder in women: do age and comorbidities make a difference?
    High RA; Winkelman W; Panza J; Sanderson DJ; Yuen H; Halder G; Shaver C; Bird ET; Rogers RG; Danford JM
    Int Urogynecol J; 2021 Jan; 32(1):149-157. PubMed ID: 32588075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sacral neuromodulation with an implantable pulse generator in children with lower urinary tract symptoms: 15-year experience.
    Groen LA; Hoebeke P; Loret N; Van Praet C; Van Laecke E; Ann R; Vande Walle J; Everaert K
    J Urol; 2012 Oct; 188(4):1313-7. PubMed ID: 22902022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of Sacral Neuromodulation in Patients with Prior Surgical Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse.
    Bartley JM; Ramirez V; Killinger KA; Boura JA; Gupta P; Gaines N; Gilleran JP; Peters KM
    Female Pelvic Med Reconstr Surg; 2017; 23(1):8-12. PubMed ID: 27636222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.
    Noblett K; Siegel S; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Berg KC
    Neurourol Urodyn; 2016 Feb; 35(2):246-51. PubMed ID: 25546568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.